Why Technology Transfer Fails: The Project Management Blind Spot in API Scale-Up

A process can be chemically perfect in the lab and still fail on the plant floor. Ask anyone who has lived through a rough technology transfer in API development, and they won’t start with a story about reaction yields – they’ll start with a story about who didn’t talk to whom.

Technology transfer is the handoff between the team that develops a process (R&D) and the team that has to run it at scale (manufacturing). It’s usually treated as a technical milestone – hand over the data, run the trial batch, move on. In practice, it’s one of the highest-risk points in the entire API development lifecycle, and the risk is rarely chemistry. It’s coordination.

The Handoff Nobody Manages

In most organizations, nobody formally owns the transfer itself. R&D owns the process. Manufacturing owns the plant. The space between them – where knowledge has to move from one team’s head to another team’s execution – often has no single accountable owner. That gap is where delays, rework, and failed validation batches come from.

This is a project management problem before it’s a technical one.

Four Ways Technology Transfer Breaks – And None of Them Are About the Chemistry

Documentation that’s complete on paper, incomplete in practice. A process description can tick every required box and still leave out the operational judgment calls the lab team made along the way – the things nobody thought to write down because they seemed obvious at the time.

Knowledge that lived with one person, not with the project. When process understanding sits in a single scientist’s head instead of being deliberately transferred through structured sessions, the project’s risk profile depends on that one person’s availability – a single point of failure most teams don’t realize they’re carrying until it’s too late.

Scale-up differences nobody planned a conversation around. Equipment, mixing behavior, and heat transfer at plant scale differ from lab scale as a matter of course. The failure isn’t that these differences exist – it’s when no one built time and cross-functional review into the plan to catch them before a validation batch.

Communication gaps between teams that don’t share a manager. R&D and plant teams often sit in different reporting lines, different locations, sometimes different companies entirely (in a CDMO context). Without someone actively coordinating across that line, information moves late, or not at all.

What a Project Manager Actually Owns During Transfer

None of the four problems above get fixed by better chemistry. They get fixed by someone doing the unglamorous work of:

• Planning the transfer as its own phase, with its own milestones – not an afterthought bolted onto lab development
• Scheduling structured knowledge-transfer sessions, not assuming documentation alone is sufficient
• Coordinating R&D, TAT (technology absorption team), and plant stakeholders who don’t naturally talk to each other
• Tracking risks and open issues through the transfer the same way they’d be tracked through any other project phase
• Confirming – explicitly, not by assumption – that the process is understood by the team that has to run it, before the first engineering batch

That’s a project management discipline, not a scientific one. And it’s exactly the kind of role that gets undervalued until the transfer that skipped it turns into a six-week investigation.

Why This Matters More in a CDMO Context

For a CDMO or CRAMS organization, a rough technology transfer isn’t just an internal delay – it’s a client-facing one. Timelines slip, client confidence erodes, and the next contract renewal conversation gets harder. Treating technology transfer as a managed, owned, cross-functional project phase – rather than a document drop followed by hope – is one of the more direct ways structured project management shows up as a competitive advantage in pharma manufacturing.

The Takeaway

The next time a technology transfer runs into trouble, resist the instinct to only ask what went wrong technically. Ask who owned the coordination, whether knowledge transfer was planned as deliberately as the trial batch was, and whether the risks were being tracked before they became problems. Most of the time, that’s where the real answer is.

This piece draws on the stage-gate project management framework used in API new product development – the same framework behind PMSoft’s upcoming project management course for the API/pharma industry.